Cellect Biotechnology (NASDAQ: APOP) is trading 26% higher mid-morning following word the company has treated the first blood cancer patient in the recently initiated phase I/II trial of its stem cell technology ApoGraft™. The intent of the trial is to assess the Cellect ApoGraft™ process which is designed to prevent Graft-versus-Host Disease (GvHD), a common complication linked to stem cell transplant. Additionally, the company expects to release definitive and complete results of its trial on healthy volunteers before the end of the first quarter this year. “Enrolling our first cancer patient to be treated using our groundbreaking method is a critical milestone for millions of patients worldwide. ApoGraft™ has been proven to be effective in assisting successful stem cells transplants and preventing GvHD during our animal studies. I am excited with prospects of Cellect becoming a key contributor to the fast-growing market for stem cells based products enabling 21st century regenerative medicine,” Cellect CEO Shai Yarkoni stated in the news release.
To view the full press release, visit: http://nnw.fm/msn3S
About Cellect Biotechnology Ltd.
Cellect Biotechnology has developed a breakthrough technology for the selection of stem cells from any given tissue for any clinical indication; a technology that aims to enable a variety of stem cells applications. The company’s technology is expected to provide pharma companies, medical research and hospitals with the tools to rapidly produce stem cells in quantity and quality that will enable commercialization of all stems cell based treatments and procedures. Cellect’s technology is applicable to a wide variety of stem cells related treatments in regenerative medicine while this specific clinical trials is aimed at the cancer treatment by bone marrow transplantations. For more information, visit http://cellectbio.com.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.NetworkNewsWire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer